News >

IMpassion130 Trial Takes Immunotherapy to Forefront of TNBC

Ellie Leick
Published: Monday, Aug 05, 2019

Eleni Andreopoulou, MD, Madeline and Stephen Anbinder Clinical Scholar, Hematology/Oncology, Medicine, associate professor of clinical medicine, Weill Cornell Medicine

Eleni Andreopoulou, MD

Findings from the phase III IMpassion130 trial, which demonstrated that atezolizumab (Tecentriq) combined with nab-paclitaxel (Abraxane) improved progression-free and overall survival (OS) in triple-negative breast cancer (TNBC), are changing standard practice, explained Eleni Andreopoulou, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication